The risk of skin condition psoriasis is high among women who suffer from long-term high blood pressure and use beta- blocker medication to treat their condition, a new study led by Shaowei Wu from Brown University reveals.
Background: Psoriasis is an immune-related chronic disease that affects about 3 percent of the U.S. population. The authors suggest prospective data on the risk of psoriasis associated with hypertension is lacking. Antihypertensive medications, especially β-blockers, have been linked to psoriasis.
How the Study Was Conducted: Authors analyzed physician-diagnosed psoriasis in a group of 77,728 women who were part of the Nurses' Health Study from 1996 to 2008. Authors identified a total of 843 incident cases of psoriasis.
Discussion: "These findings provide novel insights into the association among hypertension, antihypertensive medications and psoriasis. However, further work is necessary to confirm our findings and clarify the biological mechanisms that underlie these associations." (JAMA Dermatology. Published online July 2, 2014. doi:10.1001/jamadermatol.2013.9957. Available pre-embargo to the media at media.jamanetwork.com.)
Editor's Note: This study was supported in part by a grant from the National Institutes of Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Psoriasis Provoked or Exacerbated by Medication
In a related commentary, April W. Armstrong, M.D., M.P.H., of the University of Colorado, Denver, writes: "A critical practice gap exists in identifying the causes of psoriasis flares, especially medication-related causes. Some physicians may not consistently examine medications for their contribution to psoriasis flares. However, a careful consideration of the role of medications in psoriasis exacerbation may improve long-term psoriasis control." (JAMA Dermatology. Published online July 2, 2014. doi:10.1001/jamadermatol.2014.1019. Available pre-embargo to the media at media.jamanetwork.com.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.